| Literature DB >> 31031007 |
Chuan Yan1, Dalton C Brunson2, Qin Tang2, Daniel Do2, Nicolae A Iftimia1, John C Moore1, Madeline N Hayes1, Alessandra M Welker1, Elaine G Garcia1, Taronish D Dubash3, Xin Hong3, Benjamin J Drapkin3, David T Myers3, Sarah Phat3, Angela Volorio4, Dieuwke L Marvin3, Matteo Ligorio3, Lyle Dershowitz1, Karin M McCarthy1, Murat N Karabacak5, Jonathan A Fletcher6, Dennis C Sgroi4, John A Iafrate4, Shyamala Maheswaran3, Nick J Dyson3, Daniel A Haber7, John F Rawls8, David M Langenau9.
Abstract
Xenograft cell transplantation into immunodeficient mice has become the gold standard for assessing pre-clinical efficacy of cancer drugs, yet direct visualization of single-cell phenotypes is difficult. Here, we report an optically-clear prkdc-/-, il2rga-/- zebrafish that lacks adaptive and natural killer immune cells, can engraft a wide array of human cancers at 37°C, and permits the dynamic visualization of single engrafted cells. For example, photoconversion cell-lineage tracing identified migratory and proliferative cell states in human rhabdomyosarcoma, a pediatric cancer of muscle. Additional experiments identified the preclinical efficacy of combination olaparib PARP inhibitor and temozolomide DNA-damaging agent as an effective therapy for rhabdomyosarcoma and visualized therapeutic responses using a four-color FUCCI cell-cycle fluorescent reporter. These experiments identified that combination treatment arrested rhabdomyosarcoma cells in the G2 cell cycle prior to induction of apoptosis. Finally, patient-derived xenografts could be engrafted into our model, opening new avenues for developing personalized therapeutic approaches in the future.Entities:
Keywords: SCID; breast cancer; il2rg; immune deficient; melanoma; prkdc; rhabdomyosarcoma; xenograft; zebrafish
Mesh:
Substances:
Year: 2019 PMID: 31031007 PMCID: PMC6570580 DOI: 10.1016/j.cell.2019.04.004
Source DB: PubMed Journal: Cell ISSN: 0092-8674 Impact factor: 41.582